2ndAP helps eligible U.S. and Canadian research-use-only peptide businesses explore a transparent, partner-supported path to card processing. The program includes ongoing website compliance monitoring, preset terms, and separate underwriting review; meeting compliance requirements does not guarantee approval.

Mastercard is moving AI-assisted shopping from an industry concept toward real payment activity through Alchemy AgentCard. Here is what ecommerce and high-risk merchants should understand about authorization, fraud, disputes and operational readiness.

Mastercard has added transaction and volume fees for businesses classified as specialty merchants. In 2ndAP’s view, this is a pure money grab: the published guidance identifies new charges, but no new merchant-facing fraud-prevention service or measurable protection purchased by those fees.

Eli Lilly’s tirzepatide patent should not become a blanket ban on peptide processing. We examine Visa’s penalties, corporate pressure, and the growing threat of financial deplatforming.

Mastercard is moving toward faster investigations and broader measurement of merchant risk. Here is what card-not-present and high-risk businesses should know about the new 72-hour standard, GMAP, and protecting their processing relationship.

The FDA's July 2026 review of seven peptides could have far-reaching implications beyond healthcare. As regulators evaluate potential changes to compounding eligibility, payment processors, banks, and merchants are watching closely. Learn how increased regulatory clarity may affect merchant account approvals, underwriting standards, banking relationships, and payment processing opportunities for businesses operating in the peptide industry.

Firearms merchant accounts face new risks in 2026 — rolling reserves, frozen funds, and stricter compliance rules. Here’s what’s driving the crackdown, the red flags to watch for, and how to protect your business before a freeze forces the issue.